Page 11 - ATHM26_4
P. 11

affected environment during traumatic brain damage, which  decreased acetaminophen-induced liver damage in rat upon
          accelerates and facilitates the death of the cells.  Improvement  use of 150 mg/kg silymarin.  The potential therapeutic effect
                                                                                   22
                                              3
          of oxygen supply and blood supply to the brain cells,  of N-acetylcysteine and silymarine on lung fibrosis of mice
          correction of water and electrolyte disorders, intracranial  model has been previously reported by Solhi et al.  Silymarine
                                                                                                   23
          pressure modulation, secondary hemorrhage prevention,  therapeutic  effect  on  urinary  tract  symptoms  of  prostatic
          and  preventing  seizures  were  therapeutic  strategies  for  hyperplasia has been also reported.  The aim of this study
                                                                                          24
          reducing mortality and morbidity. For example, with high  was to assess the possible effect of Silymarine on the
          confidence, steroids have been associated with traumatic  improvement of prognosis in patients with moderate and
          brain injury due to increased mortality.  In a study in 2014,  severe traumatic brain injury.
                                          1
          there was no apparent effect of lacosamide on improving the
          prognosis of moderate to severe trauma after traumatic brain  MATERIAL AND METHODS
          injury in rats.  In another study, a positive effect of citicoline   The present study was designed as a clinical trial, which
                     7
          on the improvement of consciousness in severe brain trauma  all subjects were selected from patients aged 18 to  65 years
          patients was reported by Iranian researchers.  The effect of  suffering from moderate and severe traumatic brain injury,
                                               8
          Ginseng’s herbal remedy was reported by Chinese researchers  and with Glasgow Coma Scale (GCS) score < 12, who were
          in January 2015, which its protective effect was remained  referred to the emergency department of Valiasr Hospital in
          unresolved.  In a laboratory study on the animal samples, the  Arak. After 12 hours, the patients were recruited according to
                   9
          effects of several substances, including endocannabioids,  the general inclusion/exclusion  criteria.  All subjects were
          were associated with promising results.   N-acetylcysteine  given written informed consent after explanation of study.
                                           10
          and vitamins had significant effects in predicting and  The patients were divided into two groups of intervention
          modulating the stroke pathways of brain damage in rats.   and placebo, each group was assigned 40 individuals. Patients’
                                                         11
          The effect of beta-blockers on the improvement of prognosis  checklist with demographic and clinical data was completed
          was published in a study in 2014, but requires further  for each patient and the case and control groups were then
          examination.  Moreover, the positive effects of propranolol  matched based on age, gender and severity of traumatic brain
                    12
          for limitation of secondary injury and reduction of mortality  injury. The patients were divided into two groups of
          in patients suffering from traumatic brain injury compared  intervention and placebo, which each group was assigned 40
          to other beta-blockers.  The neuroprotective effects of  individuals. Patients’ checklist with demographic and clinical
                              13
          progesterone on the improvement of traumatic brain injuries  data was completed for each patient and the case and control
          have already been reported.  However, it’s ineffectiveness has  groups were matched based on age, gender and severity of
                                14
          been reported by another study.  A pervious study indicated  traumatic brain injury. The control group received approved
                                   15
          that estradiol improves functional outcome, after spinal cord  therapies based on the indication, and the  case group had
          injury. Moreover, they reported Tamoxifen׳s effects during  also received confirmed therapies for brain trauma in terms
          late stages of spinal cord injury, indicating its potential as  of indication, plus a 140 mg dose of silymarin every eight
          long-term alternative treatment for these patients.  Another  hours for 7 days by oral gavage (oral or gavage), and placebo
                                                  16
          study had evaluated the efficacy and side-effects of  was prescribed for the control group. After three months, the
          cyclosporine-A in improvement of consciousness and  level of prognosis of the patient according to GOS criteria
          cognitive dysfunction of patients with diffuse axonal injury  and variables such as age, gender, location (city or village),
          after traumatic brain. They suggested that the administration  the cause of the trauma (related injuries involving a fall from
          of cyclosporine-A is not effective in the improvement of  height,  car, motorcycle, and bullet) and the site of the
          consciousness and cognitive function, whereas it does not  accident (street, road, home, work ), and patient’s level of
          have any adverse effects.  Silibinin has been described as an  consciousness was recorded on the checklist based upon the
                             17
          active component of silymarin, a mixture of polyflavonoids  GCS and patient arrivals to an accident and emergency
          extracted from milk thistle. Silybin isolated from herbal plant  department (in minutes). Brain trauma were divided into
          is commonly used as a liver protection agents based upon the  three groups including mild, moderate and severe as
          hepatotoxic model.  Silibinin has also had promising results  previously described by Youmans Neurological Surgery.  The
                                                                                                         1
                         18
          for improving clinical outcomes of  Amanita  phalloides  morbidity and mortality outcomes of the patient were
          poisoning.  Silibinin may be applied as an efficacious  assessed in two moderate and severe groups regarding the
                  19
          therapeutic agent against estrogen receptor (ER)-negative  standard table as previously described by Youmans
          breast carcinoma cells. Silibinin has been also reported to  neurological surgery. As matter of fact, mortality over a three
          play an anti-neoplastic effect in many kinds of malignancies  months’ period and morbidity at the end of the three months
          including  renal  cell  carcinoma,  hepatocellular  carcinoma,  were evaluated in moderate and severe groups and then
          glioblastoma, prostate, and skin, bladder, lung, and colon  compared between the cases and controls.
          cancers.  Protective effects of silymarin against the toxic   The criteria for inclusion was: (1) patients 18 to 65 years
                20
          influence of malathion has been indicated in liver tissue of  of age and both sexes; (2) moderate and severe brain trauma
          fish based upon on the biochemical variable.  It has been  patients (with GCS score < 12); and, (3) Satisfactory informed
                                               21
          previously revealed which the use of silymarin markedly  consent for intervention from the patient. Exclusion criteria


          Nazemi Rafi—Silymarine Effects on Prognosis of TBI  ALTERNATIVE THERAPIES, JUL/AUG 2020 VOL. 26 NO. 4   9
   6   7   8   9   10   11   12   13   14   15   16